NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
school
University Rankings
subject
University Subject Rankings
insights
Subject Rankings
place
Country Rankings
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Gijs Van De Wetering
Pharmerit International - / Netherlands
Others
AD Scientific Index ID: 5483265
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Gijs Van De Wetering's MOST POPULAR ARTICLES
1-)
A systematic and critical review of the evolving methods and applications of value of information in academia and practiceL Steuten, G van de Wetering, K Groothuis-Oudshoorn, V RetèlPharmacoeconomics 31, 25-48, 2013842013
2-)
The CareWell-primary care program: design of a cluster controlled trial and process evaluation of a complex intervention targeting community-dwelling frail elderlyFGH Ruikes, ARM Meys, G van de Wetering, RP Akkermans, ...BMC Family Practice 13, 1-9, 2012302012
3-)
A model to correct for short‐run inefficiencies in economic evaluations in healthcareG Van de Wetering, WH Woertman, EMM AdangHealth economics 21 (3), 270-281, 2012262012
4-)
Time to incorporate time in cost-effectiveness analysisG van de Wetering, WH Woertman, EM AdangThe European Journal of Health Economics 13, 223-226, 2012242012
5-)
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United StatesA Chatterjee, S Shapouri, BS Manzoor, A Ravelo, K Sail, V Qendri, ...Journal of Managed Care & Specialty Pharmacy 27 (11), 1532-1544, 2021172021
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept